Gait disturbance (HP:0001288)
The term gait disturbance can refer to any disruption of the ability to walk. In general, this can refer to neurological diseases but also fractures or other sources of pain that is triggered upon walking. However, in the current context gait disturbance refers to difficulty walking on the basis of a neurological or muscular disease.
Synonyms: Abnormal gait, Impaired gait, Abnormal walk, Gait abnormalities, Gait difficulties, Gait disturbances
Comment: If possible, this term should not be used for new annotations. Rather, a more specific term should be sought.
Pubmed References: PMID:27770207
Cross References: SNOMEDCT_US:22325002, UMLS:C0575081
KEGG Pathway
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | Nicotine addiction | 9.018e-15 | 4.689e-13 | 880.41 | 28472.15 |
| 2 | GABAergic synapse | 1.354e-12 | 3.520e-11 | 359.77 | 9831.65 |
| 3 | Retrograde endocannabinoid signaling | 5.071e-9 | 6.592e-8 | 138.79 | 2650.86 |
| 4 | Morphine addiction | 8.246e-8 | 8.576e-7 | 152.51 | 2487.64 |
| 5 | Neuroactive ligand-receptor interaction | 4.661e-9 | 6.592e-8 | 88.01 | 1688.34 |
GO: Biological Process
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | anterograde trans-synaptic signaling (GO:0098916) | 5.108e-17 | 6.896e-15 | 756.57 | 28381.44 |
| 2 | chemical synaptic transmission (GO:0007268) | 4.030e-16 | 2.720e-14 | 596.76 | 21153.59 |
| 3 | chloride transmembrane transport (GO:1902476) | 3.727e-14 | 1.677e-12 | 679.98 | 21025.29 |
| 4 | synaptic transmission, GABAergic (GO:0051932) | 1.482e-8 | 2.858e-7 | 1070.46 | 19297.66 |
| 5 | inhibitory synapse assembly (GO:1904862) | 1.482e-8 | 2.858e-7 | 1070.46 | 19297.66 |
GO: Molecular Function
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | GABA-A receptor activity (GO:0004890) | 1.217e-10 | 6.310e-9 | 887.78 | 20267.77 |
| 2 | GABA receptor activity (GO:0016917) | 2.294e-10 | 6.310e-9 | 739.70 | 16417.99 |
| 3 | GABA-gated chloride ion channel activity (GO:0022851) | 2.567e-8 | 2.353e-7 | 856.29 | 14966.03 |
| 4 | ligand-gated anion channel activity (GO:0099095) | 7.315e-8 | 5.748e-7 | 570.71 | 9377.24 |
| 5 | transmitter-gated ion channel activity (GO:0022824) | 1.451e-9 | 2.659e-8 | 443.56 | 9026.96 |
GO: Cellular Component
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | neuron projection (GO:0043005) | 2.546e-16 | 6.110e-15 | 194440.00 | 6981748.76 |
| 2 | GABA-A receptor complex (GO:1902711) | 1.217e-10 | 1.460e-9 | 887.78 | 20267.77 |
| 3 | excitatory synapse (GO:0060076) | 0.00006709 | 0.0003220 | 217.03 | 2085.58 |
| 4 | neuron to neuron synapse (GO:0098984) | 0.003994 | 0.006846 | 317.19 | 1751.86 |
| 5 | NMDA selective glutamate receptor complex (GO:0017146) | 0.003994 | 0.006846 | 317.19 | 1751.86 |
Hub genes predicted as biomarkers & predicted FDA approved drugs
| Hub Genes (ranked) | FDA-Approved Drugs |
| GRIA2 | PERAMPANEL |
| GABRA1 | METHOHEXITAL, BARBITAL, THIAMYLAL, ZALEPLON, ZOPICLONE, ZOLPIDEM |
| GABRG2 | – |
| GABRB2 | – |
| GRIN1 | MEMANTINE, ORPHENADRINE |
| CAMK2A | – |
| KCNA1 | BUPIVACAINE, ISOFLURANE, DESFLURANE |
| GABRD | – |
| SLC12A5 | BUMETANIDE |
| SLC6A1 | TIAGABINE, TIAGABINE HYDROCHLORIDE |
